Quick Answer
ABVC BIOPHARMA, INC. reported Diluted EPS of $0.39 per share (loss) for fiscal year 2025.
ABVC BIOPHARMA, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.39 | +7.1% |
| 2024 | -$0.42 | +76.7% |
| 2023 | -$1.80 | +65.3% |
| 2022 | -$5.19 | -917.6% |
| 2021 | -$0.51 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.05 | -66.7% | +61.5% |
| June 30, 2025 | -$0.13 | -62.5% | -116.7% |
| March 31, 2025 | -$0.06 | +79.3% | -100.0% |
| September 30, 2024 | -$0.03 | +96.3% | +62.5% |
| June 30, 2024 | -$0.08 | +88.2% | +72.4% |
| March 31, 2024 | -$0.29 | +47.3% | +64.6% |
| September 30, 2023 | -$0.82 | +28.1% | -20.6% |
| June 30, 2023 | -$0.68 | -15.3% | -23.6% |
- ABVC BIOPHARMA, INC. showed an increase of +7.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, ABVC BIOPHARMA, INC.’s diluted eps has grown by 23.5% (from $0.51 per share (loss) to $0.39 per share (loss)).
- The most recent figure is from ABVC BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: